These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25582275)

  • 21. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples.
    Giovannetti E; Laan AC; Vasile E; Tibaldi C; Nannizzi S; Ricciardi S; Falcone A; Danesi R; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):720-5. PubMed ID: 18600531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
    Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L
    J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
    Yoon KA; Woo SM; Hong EK; Jung MK; Park WS; Bae K; Han SS; Kim TH; Koh YH; Park SJ; Lee WJ
    Oncology; 2015; 89(6):345-50. PubMed ID: 26418006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.
    Kasuya K; Tsuchida A; Nagakawa Y; Suzuki Y; Suzuki M; Aoki T; Abe Y; Shimazu M; Itoi T; Sofuni A
    Hepatogastroenterology; 2012; 59(117):1609-13. PubMed ID: 22155850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
    Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
    Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
    Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
    Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population.
    Iyer SN; Ankala A; Singhal RS; Hegde MR
    Gene; 2013 Jul; 524(1):35-9. PubMed ID: 23612254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing.
    Giovannetti E; Tibaldi C; Falcone A; Danesi R; Peters GJ
    J Clin Oncol; 2010 May; 28(14):e221-2; author reply e223-5. PubMed ID: 20351322
    [No Abstract]   [Full Text] [Related]  

  • 29. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.
    Erčulj N; Kovač V; Hmeljak J; Franko A; Dodič-Fikfak M; Dolžan V
    Pharmacogenet Genomics; 2012 Jan; 22(1):58-68. PubMed ID: 22134350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ethnic differences of genetic polymorphisms in cancer chemotherapy].
    Saijyo N
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1072-5. PubMed ID: 18633243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients.
    Abbaspour A; Dehghani M; Setayesh M; Tavakkoli M; Rostamipour HA; Ghorbani M; Ramzi M; Omidvari S; Moosavi F; Firuzi O
    Cancer Chemother Pharmacol; 2023 Dec; 92(6):475-483. PubMed ID: 37668680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.
    Ciccolini J; Dahan L; André N; Evrard A; Duluc M; Blesius A; Yang C; Giacometti S; Brunet C; Raynal C; Ortiz A; Frances N; Iliadis A; Duffaud F; Seitz JF; Mercier C
    J Clin Oncol; 2010 Jan; 28(1):160-5. PubMed ID: 19933910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
    Tibaldi C; Camerini A; Tiseo M; Mazzoni F; Barbieri F; Vittimberga I; Brighenti M; Boni L; Baldini E; Gilli A; Honeywell R; Chartoire M; Peters GJ; Giovannetti E;
    Br J Cancer; 2018 Nov; 119(11):1326-1331. PubMed ID: 30405211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
    Ueno H; Kaniwa N; Okusaka T; Ikeda M; Morizane C; Kondo S; Sugiyama E; Kim SR; Hasegawa R; Saito Y; Yoshida T; Saijo N; Sawada J
    Br J Cancer; 2009 Mar; 100(6):870-3. PubMed ID: 19293806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.
    Serdjebi C; Seitz JF; Ciccolini J; Duluc M; Norguet E; Fina F; Lacarelle B; Ouafik L; Dahan L
    Pharmacogenomics; 2013 Jul; 14(9):1047-51. PubMed ID: 23837479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
    Gusella M; Pasini F; Bolzonella C; Meneghetti S; Barile C; Bononi A; Toso S; Menon D; Crepaldi G; Modena Y; Stievano L; Padrini R
    Br J Clin Pharmacol; 2011 Mar; 71(3):437-44. PubMed ID: 21284703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy.
    Liu D; Li X; Li X; Zhang M; Zhang J; Hou D; Tong Z; Dong M
    Cancer Chemother Pharmacol; 2019 May; 83(5):939-949. PubMed ID: 30877365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene.
    Sugiyama E; Lee SJ; Lee SS; Kim WY; Kim SR; Tohkin M; Hasegawa R; Okuda H; Kawamoto M; Kamatani N; Sawada J; Kaniwa N; Saito Y; Shin JG
    Drug Metab Pharmacokinet; 2009; 24(6):553-6. PubMed ID: 20045991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
    Joerger M; Burgers SA; Baas P; Smit EF; Haitjema TJ; Bard MP; Doodeman VD; Smits PH; Vincent A; Huitema AD; Beijnen JH; Schellens JH
    Cancer; 2012 May; 118(9):2466-75. PubMed ID: 22031394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
    Mercier C; Dahan L; Ouafik L; André N; Ciccolini J
    Eur J Clin Pharmacol; 2010 Sep; 66(9):959-60. PubMed ID: 20563566
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.